Frequently Asked Questions
Aquagenic pruritus treatment market is projected to grow at a CAGR of 5.90% during the forecast period of 2022 to 2029.
The rise in the prevalence of aquagenic pruritus will act as a major market driver and further enhance the market’s growth rate. Another significant factor influencing the growth rate of the aquagenic pruritus treatment market is the rising healthcare expenditure.
The major players operating in the aquagenic pruritus treatment market are Pfizer Inc., Merck Sharp & Dohme Corp., Lupin, Eli Lilly and Company, Abbott, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bayer AG, Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson Private Limited, Sanofi, Novartis AG, Aurobindo Pharma, Mylan N.V., Dr. Reddy’s Laboratories Ltd., BASF SE, Allergan, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AbbVie Inc., Takeda Pharmaceutical Company Limited., Sumitomo Dainippon Pharma Co., Ltd., Cipla Inc., and Bristol-Myers Squibb Company, among others.
North America dominates the aquagenic pruritus treatment market due to the presence of major key players and the high prevalence rate in this region.
